[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548185":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":12,"responsibleParty":63,"collaborators":65,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":7,"enrollmentInfo":79,"targetDuration":7,"studyType":82,"phases":7,"briefSummary":83,"conditions":84,"keywords":7,"overallStatus":15,"whyStopped":7,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Zurich","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Neurological Assessment","Clinical neurological assessment performed by 2 raters",[13,33,48],{"facility":14,"status":15,"city":16,"state":17,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"MD Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":22,"coordinates":23},"Point",[24,25],-95.36327,29.76328,{"lat":25,"lon":24},[28],{"name":29,"role":30,"phone":31,"phoneExt":7,"email":32},"Barbara O'Brien","CONTACT","832-837-9347","BJOBrien@mdanderson.org",{"facility":34,"status":15,"city":35,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":42,"contacts":43},"Netherlands Cancer Institute","Amsterdam","Netherlands","NL",{"type":22,"coordinates":39},[40,41],4.88969,52.37403,{"lat":41,"lon":40},[44],{"name":45,"role":30,"phone":46,"phoneExt":7,"email":47},"Dieta Bransdma","+31 (0)20 512 9111","d.brandsma@nki.nl",{"facility":49,"status":15,"city":50,"state":7,"zip":7,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"University Hospital Zurich","Zurich","Switzerland","CH",{"type":22,"coordinates":54},[55,56],8.55,47.36667,{"lat":56,"lon":55},[59],{"name":60,"role":30,"phone":61,"phoneExt":7,"email":62},"Emilie Le Rhun","+41 44 255 38 99","emilie.lerhun@usz.ch",{"type":64,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[66,68],{"name":67,"class":6},"M.D. Anderson Cancer Center",{"name":69,"class":6},"The Netherlands Cancer Institute","100548185","standardized-clinical-assessment-of-patients-with-leptomeningeal-metastasis-100548185",false,"NCT06417710","Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis","NANO-LM","Inclusion Criteria:\n\n* Adult patients (18 years or more), female or male\n* Histologically confirmed diagnosis of extra-CNS primary solid cancer\n* Diagnosis of leptomeningeal metastases confirmed or probable per EANO ESMO criteria\n* Performance status compatible with enrolment into clinical trials\n* Ability to consent\n* Signed informed consent form from patient\n* Participation in a parallel clinical trial is allowed in this non-interventional study\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* Inability to adhere to recommended follow-up according to the treating physician\n\nVulnerable participants will not be included.","ALL","18 Years",{"count":80,"type":81},200,"ESTIMATED","OBSERVATIONAL","The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.",[85,86,87,88],"Leptomeningeal Metastasis","Leptomeningeal Disease","Leptomeningeal Neoplasms","Leptomeningeal Cancer","2024-05-12",{"date":91,"type":92},"2024-05-16","ACTUAL",{"date":94,"type":92},"2022-01-30",{"date":96,"type":81},"2026-12",{"name":5,"class":6},3]